Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Bradley S. Stolshek"'
Autor:
Stanley Cohen, Ahmed Samad, Elaine Karis, Bradley S. Stolshek, Mona Trivedi, Hao Zhang, Girish A. Aras, Greg Kricorian, James B. Chung
Publikováno v:
Rheumatology and Therapy, Vol 6, Iss 2, Pp 245-254 (2019)
Abstract Introduction Etanercept, a tumor necrosis factor inhibitor, is used to treat rheumatoid arthritis (RA) and psoriatic arthritis (PsA), and is administered via subcutaneous injection. Injection site pain (ISP) associated with subcutaneous admi
Externí odkaz:
https://doaj.org/article/c4248717f73b4a32becdd052b5ffbc3c
Autor:
Vibeke Strand, Ervant J Maksabedian Hernandez, Bradley S Stolshek, Lyrica X H Liu, David H Collier, Gregory Kricorian
Publikováno v:
RMD Open, Vol 7, Iss 1 (2021)
Objectives We examined patient-reported outcomes (PROs) in The Study of Etanercept And Methotrexate in Patients with Psoriatic Arthritis (PsA); a 48-week, phase 3, randomised controlled trial that compared outcomes with methotrexate (MTX) monotherapy
Externí odkaz:
https://doaj.org/article/cddd1c3819a245839e9b239f459eb3f3
Autor:
Ervant J Maksabedian Hernandez, Mahdi Gharaibeh, Donna McMorrow, Machaon Bonafede, Bradley S. Stolshek
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 26:1039-1049
Targeted immunomodulators (TIMs) are used for the treatment of moderate to severe rheumatoid arthritis (RA) and include biologic and nonbiologic medications with different mechanisms of action. Data describing disease activity levels in RA are not di
Autor:
Philip Chan, Joseph Tkacz, Bradley S. Stolshek, Nicole M. Zimmerman, Elaine Karis, Ervant J Maksabedian Hernandez, Alexis Ogdie, Brendan Limone
Publikováno v:
The American journal of managed care. 27(7)
Objectives To describe current psoriatic arthritis treatment and costs by provider specialty using real-world claims data. Study design Observational, retrospective cohort study of patients in the IBM MarketScan Commercial and supplemental Medicare d
Autor:
Bradley S. Stolshek, Hao Zhang, Greg Kricorian, Ahmed S Samad, Stanley Cohen, James B. Chung, Elaine Karis, Girish A. Aras, Mona Trivedi
Publikováno v:
Rheumatology and Therapy
Rheumatology and Therapy, Vol 6, Iss 2, Pp 245-254 (2019)
Rheumatology and Therapy, Vol 6, Iss 2, Pp 245-254 (2019)
Introduction Etanercept, a tumor necrosis factor inhibitor, is used to treat rheumatoid arthritis (RA) and psoriatic arthritis (PsA), and is administered via subcutaneous injection. Injection site pain (ISP) associated with subcutaneous administratio
Autor:
Ervant J Maksabedian Hernandez, David H. Collier, Joseph Tkacz, Jeroen P. Jansen, L. Moore-Schiltz, Devin Incerti, Mahdi Gharaibeh, Bradley S. Stolshek
Publikováno v:
Journal of managed carespecialty pharmacy. 26(10)
Patients with moderate to severe rheumatoid arthritis (RA) occasionally increase their doses of tumor necrosis factor (TNF) inhibitors, especially the monoclonal antibody origin drugs such as adalimumab and infliximab, after inadequate response to th
Autor:
Ervant J Maksabedian Hernandez, Bradley S. Stolshek, Lorena Lopez-Gonzalez, Joseph Tkacz, Kate Higgins, Alexis Ogdie
Publikováno v:
The American journal of managed care. 26(8)
Objectives Pharmacologic treatment for psoriatic arthritis (PsA) includes traditional oral small molecules (OSMs), tumor necrosis factor inhibitors (TNFis), and newer oral therapies such as a phosphodiesterase-4 (PDE4) inhibitor and a Janus kinase in
Publikováno v:
Journal of drugs in dermatology : JDD. 19(4)
Background: Patients with moderate-to-severe psoriasis can have symptoms resulting in significant impact on patient-reported outcomes (PROs). The effect of etanercept (ETN) in moderate-to-severe psoriasis patients who previously received apremilast (
Autor:
P. Yen, V.P. Bykerk, Bradley S. Stolshek, Paul Emery, P. Haraoui, Elaine Karis, David H. Collier, Gregory Kricorian, Jeffrey R. Curtis
Publikováno v:
Annals of the Rheumatic Diseases. 80:66.1-66
Background:Limited studies have assessed the effect of withdrawal of either methotrexate (MTX) or etanercept (ETN) on patient-reported outcomes (PROs) in rheumatoid arthritis (RA).Objectives:To evaluate the baseline and change in PROs following withd
Autor:
Bradley S. Stolshek, Mona L. Martin, Joelle M. van der Walt, Richard B. Warren, Bruce Strober, Andre V. E. de Carvalho, Peter C.M. van de Kerkhof, Claudia de la Cruz, Yves Poulin, Kristina Callis Duffin
Publikováno v:
Strober, B, van de Kerkhof, P C M, Callis Duffin, K, Poulin, Y, Warren, R B, de la Cruz, C, van der Walt, J M, Stolshek, B S, Martin, M L & de Carvalho, A V E 2019, ' Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings : A Study from the International Psoriasis Council ', American journal of clinical dermatology . https://doi.org/10.1007/s40257-019-00458-2
American Journal of Clinical Dermatology
American Journal of Clinical Dermatology, 20, 699-709
American Journal of Clinical Dermatology, 20, 5, pp. 699-709
American Journal of Clinical Dermatology
American Journal of Clinical Dermatology, 20, 699-709
American Journal of Clinical Dermatology, 20, 5, pp. 699-709
Background The Psoriasis Symptom Inventory (PSI) is a patient-reported outcome measure designed to assess psoriasis signs and symptoms. Objectives The aim was to assess the usefulness of the PSI in enhancing patient care in the clinical setting. Meth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f183beea868593a5f3904e264580b66a
https://research.manchester.ac.uk/en/publications/3659770c-9784-4088-8d14-ab0fa88ef014
https://research.manchester.ac.uk/en/publications/3659770c-9784-4088-8d14-ab0fa88ef014